THX Pharma
ALTHX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €9,732 | €4,934 | €6,517 | €8,609 |
| - Cash | €0 | €714 | €416 | €1,199 |
| + Debt | €0 | €2,871 | €2,936 | €3,643 |
| Enterprise Value | €9,732 | €7,091 | €9,037 | €11,053 |
| Revenue | €0 | €35 | €2,213 | €75 |
| % Growth | -100% | -98.4% | 2,864.1% | – |
| Gross Profit | -€48 | -€649 | €964 | -€2,593 |
| % Margin | – | -1,851.7% | 43.6% | -3,472.8% |
| EBITDA | -€1,063 | -€1,176 | -€178 | -€3,641 |
| % Margin | – | -3,355.8% | -8.1% | -4,875.7% |
| Net Income | -€1,072 | -€933 | €101 | -€3,182 |
| % Margin | – | -2,662.4% | 4.6% | -4,261.1% |
| EPS Diluted | -0.13 | -0.11 | 0.013 | -0.41 |
| % Growth | -18.2% | -946.2% | 103.2% | – |
| Operating Cash Flow | – | -€545 | -€2,280 | -€2,547 |
| Capital Expenditures | – | -€0 | -€2 | -€3 |
| Free Cash Flow | – | -€545 | -€2,282 | -€2,549 |